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ABSTRACT
Introduction There is evidence that different psychosocial 
interventions could reduce the risk of relapse in 
schizophrenia, but a comprehensive evidence based on their 
relative efficacy is lacking. We will conduct a network meta- 
analysis (NMA), integrating direct and indirect comparisons 
from randomised controlled trials (RCTs) to rank psychosocial 
treatments for relapse prevention in schizophrenia according 
to their efficacy, acceptability and tolerability.
Methods and analysis We will include all RCTs comparing 
a psychosocial treatment aimed at preventing relapse in 
patients with schizophrenia with another psychosocial 
intervention or with a no treatment condition (waiting list, 
treatment as usual). We will include studies on adult patients 
with schizophrenia, excluding specific subpopulations (eg, 
acutely ill patients). Primary outcome will be the number of 
patients experiencing a relapse. Secondary outcomes will be 
acceptability (dropout), change in overall, positive, negative 
and depressive symptoms, quality of life, adherence, 
functioning and adverse events. Published and unpublished 
studies will be sought through database searches, trial 
registries and websites. Study selection and data extraction 
will be conducted by at least two independent reviewers. We 
will conduct random- effects NMA to synthesise all evidence 
for each outcome and obtain a comprehensive ranking of all 
treatments. NMA will be conducted in R within a frequentist 
framework. The risk of bias in studies will be evaluated 
using the Cochrane Risk of Bias tool and the credibility of 
the evidence will be evaluated using Confidence in Network 
Meta- Analysis (CINeMA). Subgroup and sensitivity analyses 
will be conducted to assess the robustness of the findings.
Ethics and dissemination No ethical issues are foreseen. 
Results from this study will be published in peer- reviewed 
journals and presented at relevant conferences.
PROSPERO registration number CRD42019147884.
InTROduCTIOn
Schizophrenia is characterised by acute 
episodes often followed by symptom improve-
ment,1 but it requires generally maintenance 
treatment in order to prevent recrudescence 
of symptomatology.
A 5- year analysis of 11 291 patients with 
schizophrenia found a 13.4% rehospitalisa-
tion rate within 1 month, 38.9% within 1 year 
and 64.1% within 5 years.2
Pharmacological interventions have been 
the mainstay of treatment for schizophrenia, 
and they also play an essential role in the 
prevention of relapses. According to a recent 
meta- analysis of 65 randomised trials, patients 
treated with antipsychotics experienced a 
psychotic relapse within 1 year in 27% of the 
cases.3
Moreover, antipsychotics have a number of 
limitations (high incidence of disabling side 
Strengths and limitations of this study
 ► This will be the first network meta- analysis (NMA) 
on psychosocial treatments for relapse prevention in 
schizophrenia; the findings from this study have the 
potential to inform and influence clinical decision- 
making and guideline development.
 ► The analysis will benefit from maximum statistical 
power by combining direct and indirect comparisons 
in a NMA, measuring the relative effects of the dif-
ferent treatments.
 ► There is risk of heterogeneity and inconsistency, giv-
en the different psychosocial interventions that will 
be included; however, we try to control variability by 
carefully framing the inclusion criteria about popu-
lation, interventions and focus of the single studies, 
and we will evaluate consistency employing local as 
well as global methods.
 ► The limitations of individual studies will be ad-
dressed with the Cochrane risk of bias tool and the 
credibility of the results for the primary outcome 
will be assessed using the Confidence in Network 
Meta- Analysis web application, an adaptation of the 
GRADE framework; these approaches are consid-
ered the gold standard for critical appraisal of evi-
dence quality.
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effects, poor adherence to treatment)3 and can be prob-
lematic in many situations (such as medical comorbidi-
ties, tolerability problems and pregnancy).
The resulting burden for patients, relatives and society 
is dramatic because relapses often lead to costly hospi-
talisations; patients lose their jobs and relationships are 
challenged.4 5
In this context, psychosocial interventions might have 
an important role to reduce the risk of relapses.
Several systematic reviews and meta- analyses have exam-
ined the comparative efficacy and acceptability of psycho-
social interventions from randomised controlled trials 
(RCTs) in schizophrenia considering relapses among 
other outcomes. Different interventions such as family 
therapy,6 psychoeducation7 8 and cognitive behavioural 
therapy9 10 have been compared with the so- called no 
treatment conditions (waiting list, treatment as usual 
(TAU)),7 9 and in some cases also compared with other 
psychosocial treatments pooled together,6 10 showing 
promising results.
A review of 25 studies examining family interventions 
found a 20% reduction of relapse when involving the 
relatives in the treatment during maintenance phase.6
Psychoeducation was found to be successful in reduc-
tion of relapses in a Cochrane review analysing 11 
studies in the medium term and six studies in the long 
term comparing psychoeducation with standard care 
(RR 0.70, 95% CI 0.61 to 0.81; RR 0.73, 95% CI 0.62 
to 0.85)7; brief psychoeducation also showed positive 
results in the medium term for people with severe mental 
illnesses.8 Cognitive behavioural therapy was found to 
reduce relapse rates in the medium term when compared 
with standard care,9 but not when compared with other 
psychosocial therapies.10
However, evidence is still fragmentary and a compre-
hensive ranking of all treatments evaluated in RCTs is 
lacking.
In fact, all the available reviews applied pairwise meta- 
analysis as a method, and they can therefore provide infor-
mation only on comparisons of two treatments that have 
been considered in existing studies, and several interven-
tions lack of head- to- head comparisons. For example, 
both individual psychoeducation and family interven-
tions have shown efficacy in the reduction of relapses, but 
the two have never been compared with each other.
As a result, it is still unclear which are the most effica-
cious, the most acceptable and the best tolerable psycho-
social treatments for relapse prevention in schizophrenia. 
Better understanding of the comparative efficacy of these 
active treatments would be important for clinical practice 
and for meaningful allocation of resources.
To overcome this gap in the current knowledge, we will 
perform a network meta- analysis (NMA) comparing all 
the interventions with each other and produce hierar-
chies of the effects of the various psychosocial treatments. 
Such hierarchies are essential for guidelines, which should 
ideally be able to indicate which treatment is likely to be 
the best, the second best and so on for a given outcome. 
Only the method of NMA can provide such hierarchies by 
combining all the randomised evidence.
Objectives
To estimate relative treatment effects and obtain a hier-
archy for the psychosocial treatments for relapse preven-
tion in patients with schizophrenia, in terms of:
1. Relapse and hospitalisations.
2. Other efficacy measures: overall symptoms, positive 
symptoms, negative symptoms, depressive symptoms, 
quality of life, adherence, overall functioning.
3. Acceptability (dropout) and tolerability (adverse 
events).
METhOdS And AnAlySIS
Methods for this systematic review have been developed 
according to the Preferred Reporting Items for Systematic 
review and Meta- Analysis Protocols (PRISMA- P) checklist, 
and the PRISMA extension statement for reporting of 
systematic reviews incorporating network meta- analyses 
of healthcare interventions.11 12 This systematic review 
and NMA is registered in the PROSPERO database (regis-
tration number: CRD42019147884). The record in PROS-
PERO will be updated with any amendment made to the 
protocol. The methods are consistent with the protocol of 
a previous NMA by our group on psychological interven-
tion for the positive symptoms of schizophrenia.13
Criteria for considering studies for this review
Types of studies
RCTs will be included. We will accept open and blinded 
RCTs; this choice is particularly relevant in trials on 
psychological interventions, in which only the assessor of 
outcome can be blind, but not the clinicians providing 
the intervention. The effect of a non- blind assessor will 
be examined excluding these studies in a sensitivity anal-
ysis. In the case of cross- over studies, we will use only the 
first cross- over phase in order to avoid the problem of 
carry- over effects which are very likely in schizophrenia 
and with psychosocial treatments. Studies described as 
randomised, but in which a closer evaluation with the 
RoB V.2.0 leads to a ‘high risk of bias’ judgement in 
the domain ‘risk of bias arising from the randomization 
process’, will be excluded. There will be no language 
restriction in order to avoid the problem of ‘language 
bias’.14 Studies will be considered for inclusion irrespec-
tive of setting (inpatients or outpatients), participant 
gender, nationality and ethnicity.
For all the selection criteria (participants, interven-
tions, comparators, outcomes, study design), we will pay 
attention to the joint randomisability of the interventions 
for the studied populations namely if the included partic-
ipants are in principle jointly randomisable to a hypothet-
ical huge trial comparing all the included interventions.
Types of participants
Individuals aged 18 years or older with a diagnosis of 
schizophrenia or related disorders (schizophreniform 
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or schizoaffective disorders); there is no clear evidence 
that the latter schizophrenia- like psychoses are caused 
by fundamentally different disease processes or require 
different treatment approaches.15
We will include trials irrespective of the diagnostic 
criteria used. Here we will follow the strategy of the 
Cochrane Schizophrenia Group16 to include not only 
the studies that used specific diagnostic criteria such as 
ICD-10 or DSM- V, because these criteria are not meticu-
lously used in clinical routine either. This decision should 
increase generalisability and representativeness.
Studies including participants with other diagnoses 
part of the psychosis spectrum will be included only if 
participants with a diagnosis of schizophrenia, schizo-
phreniform or schizoaffective disorders were more than 
80% of the participants considered.
We will exclude studies where all patients, according to 
the study inclusion criteria, (1) are acutely ill (eg, showing 
agitation/aggression), but we will include studies if the 
description of the treatment implies that they are stable 
enough to receive the intervention (eg, psychoeduca-
tion initiated during hospital stay, but it is clear it will be 
offered to the patients when they are stable enough to 
take part in the sessions), (2) have comorbid psychiatric 
disorders, including substance abuse, (3) have a concom-
itant medical illness, (4) are prodromal or ‘at risk for 
psychosis’.
Types of interventions
We will include any psychosocial intervention whose 
main target in the included study is relapse prevention. 
We expect to include specific psychotherapies (eg, cogni-
tive behavioural therapy designed for relapse prevention, 
compliance therapy), non- specific psychotherapies (eg, 
supportive therapy), group psychotherapies (eg, family 
intervention, psychoeducation), interventions focused 
on psychosocial functioning (eg, social skills training), 
interventions including the broader context in which the 
patient lives (eg, case management and assertive commu-
nity treatment).
The interventions mentioned above are typical exam-
ples. Nevertheless, if during the screening process we 
identify studies meeting inclusion criteria that examine 
other interventions we will include them as long as they 
are deemed jointly randomisable with those mentioned 
above.
The interventions can be of any length. Psychosocial 
treatments as defined above will be compared with each 
other and to any non- pharmacological control condi-
tion. Control conditions will include no additional treat-
ment (eg, TAU), waiting list and inactive treatments (eg, 
psychological placebo). When TAU is used as a waiting 
list, we will classify this condition as waiting list.
Outcome measures
Primary outcome
Our primary outcome is relapse. In case more measures 
of relapse are reported, we will give priority to measures 
defined in the following order: (1) operationalised 
criteria, (2) psychiatric hospital admissions, (3) clinical 
judgement and (4) need for additional medication or for 
extra psychotherapy sessions/meetings with the therapist. 
Other definitions that we cannot foresee at the protocol 
stage will also be discussed and considered for inclusion. 
We will extract the number of patients who relapsed and 
the definition that was used by the authors.
Dropouts will be considered as having relapsed in a 
sensitivity worst case scenario analysis, unless it is clear 
that they have already been counted among relapsed 
patients by the authors of the study.
Primary outcome relapse will be reported separately up 
to 6 months (26 weeks), up to 12 months (between 26 and 
52 weeks—primary time point), more than 12 months.
We want to include studies in which the psychosocial 
treatment aims at preventing relapse. Therefore, studies 
will be included if relapse or rehospitalisation is measured 
among the primary outcomes according to the protocol 
or methods of the trial.
Where not explicitly reported in the study methods or 
protocol, the judgement about whether relapse or rehos-
pitalisation can be considered as primary or co- primary 
outcome will be made observing:
 ► Whether it is mentioned in the title (eg, ‘psychoedu-
cation for relapse prevention in schizophrenia’).
 ► Whether it is the only outcome measured in the study.
 ► Whether it is declared among study aims (eg, ‘the 
main objective of this study was to examine the efficacy 
of family intervention to prevent rehospitalisation’).
 ► Whether the power calculation was planned to detect 
differences in the outcome relapse or rehospitalisation.
Studies in which there is a declared primary outcome 
other than relapse or rehospitalisation will be excluded. 
The exact criterion used for the judgement about 
inclusion of each study will be reported for the seek of 
transparency.
For a study to be included, the assessment of the 
outcome must have been performed at minimum 12 
weeks from randomisation.
Secondary outcomes
1. Acceptability: number of premature discontinuation 
(‘dropout’), reported separately due to any reason, 
due to inefficacy and due to worsening of clinical 
conditions. All- cause discontinuation due to any rea-
son combines efficacy, tolerability and other factors 
and can therefore be considered as a measure of ‘ac-
ceptability of treatment’16 or of overall ‘effectiveness’.
2. Change in overall symptoms, measured by rating 
scales such as the Positive and Negative Syndrome 
Scale (PANSS) or the Brief Psychiatric Rating Scale 
(BPRS), or any other published scale for the assess-
ment of overall schizophrenic symptomatology.
3. Change in positive symptoms, measured by the re-
spective subscale of the PANSS, or the ‘Scales for 
Assessment of Positive Symptoms’ or any other pub-
lished scale.
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4. Change in negative symptoms, measured by the re-
spective subscale of the PANSS, or the ‘Scales for 
Assessment of Negative Symptoms’ or any other pub-
lished scale.
5. Depressive symptoms, measured by the Calgary 
Depression Scale for Schizophrenia, the Hamilton 
Depression Rating Scale, the Montgomery Asberg 
Depression Scale or other published symptom scales.
6. Quality of life, measured by any published rating 
scale (eg, ‘Heinrichs quality of life scale’, ‘Quality of 
Life Scale’.
7. Adherence, measured by any published rating 
scale (eg, ‘Adherence Therapy Patients Satisfaction 
Questionnaire’, ‘Adherence Rating Scale’).
8. Overall functioning measured by rating scales such 
as the Global Assessment of Functioning or the 
Psychosocial Performance Scale, or any other pub-
lished rating scale.
9. Tolerability: adverse events. We will collect any re-
ported adverse event that may be connected to the 
intervention, using a recently published classifica-
tion17: (1) emergence of new symptoms; (2) deterio-
ration of existing symptoms; (3) lack of improvement 
or deterioration of illness; (4) prolongation of treat-
ment; (5) patient’s non- compliance; (6) strains in 
the patient–therapist relationship; (7) very good 
patient–therapist relationship, therapy dependency; 
(8) strains or changes in family relations; (9) strains 
or changes in work relations; (10) any change in the 
life circumstances of the patient; (11) stigmatisa-
tion. Suicide attempts and any other possible adverse 
event related to psychosocial treatment will also be 
considered.
10. Mortality. We will examine this outcome in terms of 
(1) death for any reason, (2) death due to natural 
causes and (3) due to suicide.
Secondary outcomes will be measured at study 
endpoint. If multiple time points are given, we will take 
that between 26 and 52 weeks and the closest to 52 weeks.
We will give preference to the mean change from 
baseline to endpoint measures, and, if not available, we 
will take the mean values at endpoint. All continuous 
outcomes will be measured with rating scales that have 
been published in a peer- reviewed journal, because it has 
been shown that non- validated schizophrenia scales exag-
gerate differences.18 Examples of scales that we will use 
are the PANSS, the BPRS for overall symptoms and their 
respective subscales for positive and negative symptoms 
(see above).
Search strategy
Electronic searches
The following sources will be searched without restrictions 
for language or publication period: EMBASE, MEDLINE, 
PsycINFO, PubMed, BIOSIS and the clinical trials regis-
ters Cochrane Central Register of Controlled Trials 
(CENTRAL),  ClinicalTrials. gov and WHO International 
Clinical Trials Registry Platform. A draft search strategy 
for PsycINFO is presented in table 1. The date of the last 
search update will be provided in the final publication.
Reference lists and other sources
We will also inspect previous reviews concerning psycho-
social interventions for relapse prevention/maintenance 
treatment for schizophrenia to check if some studies meet 
our inclusion criteria as well. In addition, we will contact 
the first author of each included study published in the 
last 20 years for missing information about their studies.
Identification and selection of studies
Studies identiﬁed through electronic and manual 
searches will be listed with citation, titles and abstracts, 
in Citavi; duplicates will be excluded. The eligibility for 
inclusion process will be conducted in two separate stages:
1. Two authors will independently inspect title and 
abstracts identified in the literature searches, and 
exclude those not pertinent. Disagreement will be re-
solved by discussion, and where doubt still remains we 
will acquire the full article for further inspection and 
the article will proceed to the next stage.
2. Once the full articles are obtained, at least two review-
ers will independently assess them for eligibility against 
the review criteria. If disagreement cannot be clarified 
by discussion, it will be resolved with a third review-
er (SL) or seeking further information from the study 
authors.
data extraction
Two authors will independently extract data from all 
selected trials. When disagreement arises we will resolve 
it by discussion and, if needed, by involving a third senior 
author. Where this is not sufficient, we will contact the 
study authors.
The following data will be collected from each included 
study:
 ► Study citation, year(s) of study, registration number 
to trial registries, year of publication, location, setting, 
number of centres, sample size, diagnostic criteria, 
funding/sponsor.
 ► Methodology, including study design (type of RCT), 
number of arms, risk of bias (see below).
 ► Characteristics of study participants, including 
gender, age, details on diagnosis, number randomised 
to each arm, sociodemographic characteristics, 
whether psychosocial treatments naïve at baseline 
or with previous experience with the experimental 
intervention.
 ► Characteristics of intervention, including number 
and frequency of sessions, therapy setting, expertise 
of therapist, researcher allegiance at study arm level.
 ► Outcome measures, including information on 
whether an Intention to Treat approach has been 
used and how it was defined.
The two reviewers will independently input data into 
a Microsoft Access database specifically created for this 
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Table 1 Draft search strategy for PsycINFO
1 exp Schizophrenia/
2 exp psychosis/
3 schizo$.mp.
4 or/1–3
5 exp psychotherapy/ or exp Behavior Therapy/ or exp Cognitive Therapy/ or exp PSYCHOANALYSIS/ or exp psychotherapeutic 
counseling/ or hypnosis/ or free association/
6 (abreaction or “acceptance and commitment therapy” or acting out or adlerian or analytical psychotherap$ or anger control or 
anger management or animal therap$ or art therap$ or assertive$ training or attention training technique or autogenic training 
or autosuggestion or aversion therap$ or balint group or befriending or behavio?r contracting or behavio?r modification or 
behavio?r regulation or behavio?r therap$ or bibliotherap$ or biofeedback or body psychotherap$ or brief psychotherap$ or 
caregiver support or cbt or client cent$ or cognitive behavio?r$ or cognitive intervention$ or cognitive rehabilit$ or cognitive 
remediation or cognitive technique$ or cognitive therap$ or cognitive treatment$ or colo?r therap$ or compassionate mind 
training or conjoint therap$ or contingency management or conversational therap$ or conversion therap$ or coping skills 
or counsel?ing or countertransference or couples therap$ or covert sensitization or crisis intervention or dance therap$ or 
dialectic$ or eclectic or emotion$ focus$ or emotional freedom technique or encounter group therap$ or existential therap$ 
or experiential psychotherap$ or exposure therap$ or expressive psychotherap$ or eye movement desensiti?ation or family 
intervention$ or family therap$ or feminist therap$ or free association or freudian or geriatric psychotherap$ or gestalt therap$ 
or griefwork or group intervention$ or group psychotherap$ or group therap$ or guided image$ or holistic psychotherap$ 
or humanistic psychotherap$ or hypnosis or hypnotherap$ or hypnoti?zability or imagery or implosive therap$ or individual 
psychotherap$ or insight therap$ or integrated psychological therapy or integrative psychotherap$ or integrative therap$ or 
interpersonal or jungian or kleinian or logotherap$ or marathon group therap$ or marital therap$ or meditation or mental healing 
or metacognitive therap$ or metacognitive training or milieu therap$ or mindfulness or morita therap$ or multimodal or music 
therap$ or narrative therap$ or nondirective therap$ or object relations or person cent$ therap$ or personal construct therap$ 
or persuasion therap$ or pet therap$ or play therap$ or primal therap$ or problem solving or psychoanaly$ or psychodrama 
or psychodynamic or psychoeducat$ or psychologic$ or psychological therap$ or psychosocial treatment or psychotherap$ 
or psychotherapeutic counsel$ or psychotherapeutic processes or psychotherapeutic training or psychotherapeutic 
treatment$ or rational emotive or reality therap$ or reciprocal inhibition or rehabilitat$ or relationship therap$ or relaxation or 
reminiscence therap$ or rogerian or role play$ or self analys$ or self esteem or sensitivity training or sex therap$ or sleep phase 
chronotherap$ or social skills education or social skills training or socioenvironmental therap$ or sociotherap$ or solution 
focused or stress management or support group$ or supportive therap$ or systematic desensiti?ation or systemic therap$ 
or therapeutic communit$ or transactional analysis or transference or transtheoretical or validation therap$ or (dream$ adj3 
analys$) or (support adj3 psycho$)).mp.
7 or/5–6
8 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).mp.
9 (random$ adj5 (assign$ or allocat$)).mp.
10 randomi$.mp.
11 crossover.mp.
12 or/8–11
13 4 and 7 and 12
study. The software will automatically detect any inconsist-
encies, and they will be resolved by discussion.
Measurement of treatment effect
Relative treatment effects
 ► Dichotomous outcomes: the effect size for dichoto-
mous outcomes will be the OR and its 95% CIs.
 ► Continuous outcomes: for continuous outcomes we 
will use the standardised mean difference (SMD), 
because we expect that the studies can use different 
rating scales of schizophrenia symptomatology.
Relative treatment ranking
We will estimate the probability for each intervention to 
be ranked at each possible place, given the relative effect 
sizes as estimated in NMA. As described in Salanti et al,19 
we will obtain a hierarchy of the competing interven-
tions using the Surface Under the Cumulative Ranking 
curve (SUCRA) and mean ranks. SUCRA values will be 
expressed as percentage, showing the relative probability 
of an intervention to be among the best options.
Dealing with missing outcome data and missing statistics
For dichotomous outcomes, everyone allocated to the 
intervention will be counted whether they completed the 
follow- up or not. If the authors applied such a strategy, we 
will use their results. For our primary outcome relapse this 
means we will consider patients who dropped out as having 
relapsed in a sensitivity worst case scenario analysis, unless 
the authors have already included data of these patients.
For continuous outcomes we will extract data for all 
randomised patients if possible, and we will give prefer-
ence to data based on mixed- effect models of repeated 
measurements of multiple imputations over last- 
observation- carried- forward data.
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We will use published SDs, where available. When stan-
dard errors instead of SDs are presented, the former will 
be converted to SDs.20 If both are missing we will estimate 
SDs from p values or CIs, as described in Section 7.7.3 
of the Cochrane Handbook for Systematic Reviews.21 If none 
of these options is viable, we will contact the original 
authors. When no information can be obtained, we will 
derive SDs from those of the other studies using a vali-
dated imputation technique.20
Risk of bias assessment
Risk of bias will be assessed for each included study using 
the revised Cochrane risk of bias tool, RoB V.2.0.22 IB and 
a second reviewer will independently assess the following 
domains:
1. Risk of bias arising from the randomisation process.
2. Risk of bias due to deviations from the intended inter-
ventions (effect of assignment to intervention).
3. Risk of bias due to missing outcome data.
4. Risk of bias in measurement of the outcome.
5. Risk of bias in selection of the reported result.
6. Overall risk of bias, as calculated by the algorithm de-
scribed in Sterne et al.22
Two independent review authors will assess the risk of 
bias in selected studies. Any disagreement will be resolved 
through discussion. Where necessary, the authors of the 
studies will be contacted for further information. Effects 
of studies with high risk of bias in the Overall domain will 
be analysed by sensitivity analyses.
data analysis
Characteristics of the included studies
We will produce descriptive statistics and study popula-
tion characteristics across all eligible trials, describing the 
types of comparisons and other clinical or methodolog-
ical variables, such as age, duration of illness, co- medica-
tion, country, duration of study and number of sessions.
Pairwise meta-analyses
In the first step we will perform series of conventional pair-
wise meta- analyses by combining studies that compared 
the same interventions, including the comparison 
between active treatments and the different control arms. 
If very few RCTs are available or the requirements of NMA 
are not met, it can be that NMA will not be appropriate 
and, in this case, conventional pairwise meta- analysis will 
be applied. As heterogeneity is likely, a random- effects 
model will be used.
Assessment of heterogeneity
The heterogeneity (variability in relative treatment effects 
within the same treatment comparison) will be measured 
with the tau- squared (the variance of the random effects 
distribution). The heterogeneity variance will be assumed 
common across the various treatment comparisons 
(grouped by comparison type) and we will compare the 
empirical distribution with predictive distributions.23–25 
Potential reasons for heterogeneity will be explored by 
subgroup analysis (see below).
Assessment of the transitivity assumption
Joint analysis of treatments can be misleading if the 
network is substantially intransitive. We assume that 
patients who fulfil the inclusion criteria are equally likely 
to be randomised to any of the interventions of interest 
(ie, jointly randomisable). When additional evidence of 
intransitivity is lacking and potential effect modifiers have 
similar distributions across the included studies, NMA is 
likely to give valid results. We will maximise the chances 
of transitivity in our network with regard to clinical vari-
ables by limiting our samples to participants with schizo-
phrenia and excluding specific subgroups like acutely ill 
patients or patients with a comorbid disorder.
Assessment of the transitivity assumption will be done 
by investigating the distribution of clinical and method-
ological variables that can act as effect modifiers across 
treatment comparisons.26
These variables include administration mode and 
frequency of the treatment (individual/group setting, 
number of sessions), baseline severity and blinding (see 
the Investigation of heterogeneity and inconsistency 
section), which will also be assessed in subgroup analyses. 
We will investigate if these variables are similarly distrib-
uted across studies grouped by comparison.
Network meta-analysis
NMA combines direct and indirect evidence for all rela-
tive treatment effects and can therefore provide estimates 
with maximum power and increased precision.27 If under-
taking a NMA is deemed appropriate as described above, 
we will conduct a random- effects NMA in a frequentist 
setting to synthesise all evidence for each outcome. If the 
estimation of the relative treatment effects is precise, then 
we will obtain a ranking of all treatments using the SUCRA 
and the mean ranks. We will assume a single heteroge-
neity parameter for each network. We will present the 
summary ORs or SMDs for all pairwise comparisons in a 
league table. We will also estimate the prediction intervals 
to assess how much the common heterogeneity affects the 
relative effect with respect to the extra uncertainty antici-
pated in a future study.
Assessment of inconsistency
The strategical and conceptual evaluation of transitivity 
will be supplemented with a statistical evaluation of 
consistency, the agreement between direct and indirect 
evidence.
To evaluate inconsistency, we will employ both local 
and global methods.28 We will employ the ‘separating 
indirect from direct evidence approach’, which sepa-
rates direct evidence from indirect evidence and then 
evaluates their agreement to evaluate local consistency.29 
We will also evaluate consistency in the entire network 
with the design- by- treatment interaction test.30 Tests 
for inconsistency are known to have low power, and 
empirical evidence has suggested that 10% of evidence 
loops published in the medical literature are expected 
to be inconsistent.31 Therefore, interpretation of the 
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statistical inference about inconsistency will be carried 
out with caution and possible sources of inconsistency 
will be explored even in the absence of evidence for 
inconsistency.
Investigation of heterogeneity and inconsistency
We expect small amounts of heterogeneity and inconsis-
tency to be present. The following potential effect modi-
fiers of the primary outcome will be explored by subgroup 
analyses:
1. Studies conducted in first episode patients.
2. Studies using different definitions of relapse (if rele-
vant).
3. Setting: individual versus group.
4. Setting: inpatients versus outpatients (at enrolment in 
the study).
5. Number of sessions.
6. Baseline severity (PANSS or BPRS score at baseline).
Sensitivity analyses on the primary outcome will be 
performed as follows:
1. Exclusion of studies in which the outcome assessor was 
not blind (open studies).
2. Exclusion of studies that presented only completer 
analyses.
3. Exclusion of studies with high risk of bias in the overall 
domain.
4. Exclusion of studies with researchers’ allegiance.32–34
5. Patients who dropped out from the study considered 
as having relapsed (unless data about these patients 
were already considered by study authors in the out-
come provided in the study).
6. Hospitalisations and relapse defined with other crite-
ria analysed separately.
7. Exclusion of studies where relapse or hospitalisation 
was not defined explicitly as primary outcome but 
based on our judgement.
Publication bias
To assess small study effects and publication bias, we will 
use funnel plots of pairwise meta- analyses if 10 or more 
studies are included. We will also use a comparison- 
adjusted funnel plot for relative treatment effects between 
all active and control interventions.35
Statistical software
The analysis and presentation of results will be performed 
using R (meta and netmeta packages).
Assessment of the confidence in the evidence from NMA
The confidence in the relative treatment effect esti-
mated in NMA for the primary outcome will be evaluated 
using the Confidence in Network Meta- Analysis frame-
work,28 36 implemented in the web application (http:// 
cinema. ispm. ch/ model/ CINeMA_ paper. pdf). This tool 
evaluates the credibility of the findings across the domains 
of within- study bias, across- study bias, indirectness, impre-
cision, heterogeneity and incoherence.
PATIEnT And PuBlIC InvOlvEMEnT
Representatives from the Organisation ‘BASTA—Bündnis 
für psychisch erkrankte Menschen’ were involved since 
the stage of grant application with regular meetings. We 
explained them the basis of systematic reviews method-
ology, so that they can understand the process and provide 
suggestions. We asked them to provide the patients’ 
perspective about the relevance of the topic, the choice 
and the importance of the appropriate outcomes. They 
were involved again for the preparation of this protocol, 
and one of them (WPH) is a co- author. We will collabo-
rate at the preparation of a lay version of the results that 
will be disseminated also through the newsblog of BASTA 
(http://www. bastagegenstigma. de/).
EThICS And dISSEMInATIOn
Findings will be published in peer- reviewed scientific 
journals, granting open access and the data set will be 
made publicly available.
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